logo
Only 5% of students in medical schools from lowest socio-economic group

Only 5% of students in medical schools from lowest socio-economic group

Yahoo27-02-2025

Only a fraction of medical students are from working class backgrounds despite efforts to widen access to the profession, a report has suggested.
A small number of schools and colleges produce a high number of applicants to medical school, according to research by the Sutton Trust.
Applicants from private schools were 1.5 times more likely to receive an offer to study medicine compared to those from non-selective state schools, the study suggested.
The report, which includes an analysis of nearly 94,000 applicants in England to UK medical schools between 2012 and 2022, found just 5% of entrants were from the lowest socio-economic group in 2021.
In contrast, 75% of entrants to medical schools were from higher socio-economic backgrounds in 2021, according to the research.
While still low, the proportion of those from lower socio-economic backgrounds has doubled since 2012, the report said.
The study used the National Statistics Socio-economic Classification (NS-SEC) groupings of parental occupation to determine the socio-economic status of applicants.
Applicants from lower and intermediate socio-economic backgrounds were 'less likely' to get an offer than their better-off peers, according to the report which included an analysis by University College London (UCL) academics.
The study found that a 'major factor' in this was prior educational attainment, as these students had, on average, lower GCSEs, predicted A-levels, and lower results on the University Clinical Aptitude Test (Ucat) for medical schools.
The Ucat test may be a 'barrier' for those from worse-off homes, according to the Sutton Trust report.
Standard entry A-level requirements range from AAA to A*A*A in all medical schools bar one – with one of the new medical schools asking for AAB.
But the report found that most medical schools now give some kind of contextual offer for applicants from under-represented backgrounds – and an increasing number have introduced alternative entry routes to medicine.
Seventeen medical schools have 'gateway' courses – which have lower grade requirements for eligible applicants and an additional foundation year before the standard medical school programme.
The lowest contextual offers at some medical schools is BBB for participants in their own access to medicine programmes, according to the research.
Of the 2,719 schools or colleges that put forward any medical applicants between 2012 and 2022, the study found that the majority (80%) had few students applying for medicine – at five or fewer per year.
But 58 schools or colleges – comprising just 2% of all institutions – had an average of 20 or more applicants per year.
One had more than 850 applicants over the 10-year period – an average of 85 applicants per year.
Even after adjusting statistically for their exam grades, socio-economic status and other demographic factors, private school applicants had higher odds of receiving an offer than those from non-selective state schools, the report said.
The charity is calling for the Government to prioritise medical schools with a successful, widening participation record in any expansion of spaces to improve the socio-economic mix of students.
Medical schools should be properly resourced to fully support students from lower socio-economic backgrounds and they should make more ambitious use of contextual offers and review their use of Ucat in admissions, it added.
Nick Harrison, chief executive of the Sutton Trust, said: 'It's outrageous that working-class kids make up just 5% of medical students, especially when the NHS is facing a chronic shortage of doctors and a heavy reliance on overseas recruitment.
'The medical profession is stretched to breaking point, and urgent action is needed to widen access and create a more diverse pipeline of talent from all parts of society.
'Patients benefit from doctors who reflect the diversity of the communities they serve, but it's clear that we're a long way from that today.
'If you have the ability, where you grow up or your parents' income shouldn't be a barrier to becoming a doctor.
'Working-class entry into medicine is in a critical condition. The profession urgently needs a shot of equality.'
Professor Katherine Woolf, professor of medical education research at UCL Medical School, said: 'Despite the many changes medical schools have made over the past decade to improve access to the profession, our research has shown low prior attainment remained a major barrier to many aspiring doctors from the poorest backgrounds.
'Providing enough doctors to meet the country's needs will require better support for future doctors, especially those from disadvantaged backgrounds.
'This support is needed at all stages of a doctor's career: from school, before and during application to medical school, and throughout the many years of medical education and training that are essential to practise as a doctor.'
Ohemaa Asare, British Medical Association (BMA) medical students committee deputy co-chair (widening participation), said: 'These results are hugely disappointing but unfortunately not surprising as there is still a very long way to go to ensuring medicine is more accessible to students from underrepresented or disadvantaged backgrounds.
'It is such a shame that there are many aspiring and talented doctors of the future who could make a valuable contribution to medicine and the NHS but are being hindered by many hidden barriers.'
Clare Owen, director of education at the Medical Schools Council (MSC), said medical schools have made 'significant progress' in widening participation over the past decade.
She said: 'Entrants from deprived areas have doubled to 14%, and state school representation has risen from 47% to 54%. Meanwhile, independent school acceptances have dropped from 29% to 24%.
'However as noted in the Sutton Trust study, students from lower-socio-economic backgrounds still face challenges.'
A recent report outlined the MSC's action plan to address such barriers, including: developing targeted widening participation programmes and exploring the potential of contextual admissions.
Ms Owen added: 'By 2032, medical schools aim to have 33% of students from disadvantaged backgrounds, representing almost 6,000 students annually.
'Achieving this goal will require a sector-wide effort, and we look forward to working closely with the Sutton Trust and other key stakeholders to improve access to the medical profession.'
A Government spokesperson said: 'While we inherited an education system with a number of baked-in inequalities, our ambitious Plan for Change sets out our clear mission to break the link between background and success.
'We will act to address the persistent gaps for different student groups and to break down the barriers to opportunity.
'While we have announced a 3.1% increase in loans for living costs for 2025/26, it's vital that all HE providers play a strong role in expanding access and improving outcomes for disadvantaged students.
'This Government is committed to growing our own homegrown talent, and training thousands more doctors.
'We will work with partners including NHS England and the university sector to ensure that everyone has an opportunity to study medicine – regardless of their background.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Yahoo

time3 days ago

  • Yahoo

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

NEW HAVEN, Conn., June 5, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 20,010,000 shares of its common stock at a public offering price of $5.75 per share, which includes 2,610,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the public offering at the public offering price, less underwriting discounts and commissions. The total proceeds of the public offering were approximately $115.1 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering were sold by Trevi. Morgan Stanley, Leerink Partners, Stifel and Cantor acted as joint book-running managers for the offering. The shares were offered by Trevi pursuant to a shelf registration statement on Form S-3 (File No. 333-273030), which was filed with the Securities and Exchange Commission (SEC) on June 29, 2023, amended on August 11, 2023 and declared effective by the SEC on August 15, 2023. This offering was made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. The final terms of the offering are disclosed in a final prospectus supplement which has been filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@ Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@ Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@ or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, New York 10022, or by email at prospectus@ This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Investor Contact Jonathan CarlsonTrevi Therapeutics, Inc.(203) 654 3286carlsonj@ Media Contact Rosalia Scampoli914-815-1465 rscampoli@ View original content to download multimedia: SOURCE Trevi Therapeutics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

First bacteria we ever meet can keep us out of hospital
First bacteria we ever meet can keep us out of hospital

Yahoo

time3 days ago

  • Yahoo

First bacteria we ever meet can keep us out of hospital

The first bacteria our bodies meet – in the hours after we're born – could protect us from dangerous infections, UK scientists say. They have shown, for the first time, that good bacteria seem to halve the risk of young children being admitted to hospital with lung infections. The researchers said it was a "phenomenal" finding and could lead to therapies that boost good bacteria in babies. Our early encounters with microbes are thought to be crucial in how our immune system develops. We come out of the womb sterile, but this doesn't last for long. All the nooks and crannies of the human body become home to a world of microbial life, known as the microbiome. More than half your body is not human Microbiome podcast: The Second Genome Researchers at University College London and the Sanger Institute investigated the earliest stages in our body's colonisation by bacteria, fungi and more. They collected stool samples from 1,082 newborns in the first week of life. The team then performed a massive genetic analysis on all the DNA in the samples to work out exactly which species were present and how common they were in each child. They then tracked what happened to those babies, using hospital data, for the next two years. One particular early inhabitant of the human body, Bifidobacterium longum, seemed to have a protective effect. Only 4% of babies with this species would spend a night in hospital with a lung infection over the next two years. Babies with different starter-bacteria were two-to-three times more likely to need to stay in hospital. It is the first data to show the formation of the microbiome affects the risk of infection. "I think it's really phenomenal. It's amazing to be able to show this. I'm excited," Prof Nigel Field, from UCL, told the BBC. The most likely culprit for children ending up in hospital is respiratory syncytial virus (RSV), but what joins the dots between this and B. longum? That is the "million dollar question" for Prof Field. We know B. longum starts off digesting breast milk which both contains food for the baby and encourages good bacteria. The exact details have not yet been worked out, but either the bacteria themselves or the compounds they make by digesting food are interacting with the immune system "and are influencing the way in which the immune system matures and is able to recognise friend from foe," according to Prof Field. The protective bacteria were found only in babies that came into the world via a vaginal delivery rather than a caesarean. Even then they were not discovered after every vaginal delivery. The researchers say their findings do not justify the practice of vaginal seeding, where some new parents smear babies with a swab taken from the vagina. How method of birth alters babies' bacteria The good bacteria seem to be coming from the end of the mother's digestive system, an idea known in the field as the "first lick". "I feel pretty confident in saying that vaginal seeding is not a good thing," said Prof Field. However, the long-term ambition is to come up with microbial therapies – like a probiotic yogurt – that could be given to babies to set their microbiomes on a healthy path. Prof Louise Kenny, from the University of Liverpool and a consultant obstetrician and gynaecologist, said: "A caesarean section is often a life-saving procedure, and can be the right choice for a woman and her baby." She said that while the benefit was seen only in babies born vaginally, it was not in every child born that way so "further research is needed to create a full, nuanced picture".

First bacteria we ever meet can keep us out of hospital
First bacteria we ever meet can keep us out of hospital

Yahoo

time3 days ago

  • Yahoo

First bacteria we ever meet can keep us out of hospital

The first bacteria our bodies meet – in the hours after we're born – could protect us from dangerous infections, UK scientists say. They have shown, for the first time, that good bacteria seem to halve the risk of young children being admitted to hospital with lung infections. The researchers said it was a "phenomenal" finding and could lead to therapies that boost good bacteria in babies. Our early encounters with microbes are thought to be crucial in how our immune system develops. We come out of the womb sterile, but this doesn't last for long. All the nooks and crannies of the human body become home to a world of microbial life, known as the microbiome. More than half your body is not human Microbiome podcast: The Second Genome Researchers at University College London and the Sanger Institute investigated the earliest stages in our body's colonisation by bacteria, fungi and more. They collected stool samples from 1,082 newborns in the first week of life. The team then performed a massive genetic analysis on all the DNA in the samples to work out exactly which species were present and how common they were in each child. They then tracked what happened to those babies, using hospital data, for the next two years. One particular early inhabitant of the human body, Bifidobacterium longum, seemed to have a protective effect. Only 4% of babies with this species would spend a night in hospital with a lung infection over the next two years. Babies with different starter-bacteria were two-to-three times more likely to need to stay in hospital. It is the first data to show the formation of the microbiome affects the risk of infection. "I think it's really phenomenal. It's amazing to be able to show this. I'm excited," Prof Nigel Field, from UCL, told the BBC. The most likely culprit for children ending up in hospital is respiratory syncytial virus (RSV), but what joins the dots between this and B. longum? That is the "million dollar question" for Prof Field. We know B. longum starts off digesting breast milk which both contains food for the baby and encourages good bacteria. The exact details have not yet been worked out, but either the bacteria themselves or the compounds they make by digesting food are interacting with the immune system "and are influencing the way in which the immune system matures and is able to recognise friend from foe," according to Prof Field. The protective bacteria were found only in babies that came into the world via a vaginal delivery rather than a caesarean. Even then they were not discovered after every vaginal delivery. The researchers say their findings do not justify the practice of vaginal seeding, where some new parents smear babies with a swab taken from the vagina. How method of birth alters babies' bacteria The good bacteria seem to be coming from the end of the mother's digestive system, an idea known in the field as the "first lick". "I feel pretty confident in saying that vaginal seeding is not a good thing," said Prof Field. However, the long-term ambition is to come up with microbial therapies – like a probiotic yogurt – that could be given to babies to set their microbiomes on a healthy path. Prof Louise Kenny, from the University of Liverpool and a consultant obstetrician and gynaecologist, said: "A caesarean section is often a life-saving procedure, and can be the right choice for a woman and her baby." She said that while the benefit was seen only in babies born vaginally, it was not in every child born that way so "further research is needed to create a full, nuanced picture".

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store